CD33 and acute myeloid leukemia: In vivo and in vitro experiments have demonstrated that this system can continuously release fully humanized anti-CD33-anti-CD3 bispecific antibody (bsAb), efficiently redirecting CD3+ T lymphocytes to CD33+ AML mother cells for exerting anti-tumor effects [124].